Impact of preoperative chemotherapy cycles on tumor resectability and surgical timing in hepatoblastoma: a retrospective analysis

术前化疗周期对肝母细胞瘤肿瘤切除率和手术时机的影响:一项回顾性分析

阅读:1

Abstract

BACKGROUND: Hepatoblastoma (HB) is the most common malignant liver tumor in children. However, the optimal duration of preoperative chemotherapy remains unclear, particularly regarding its impact on tumor size and proximity to critical blood vessels. METHODS: This retrospective study analyzed 24 patients with HB treated at Shanghai Xinhua Hospital from 2006 to 2022. All patients underwent neoadjuvant chemotherapy. Tumor size and distances to key vasculature, including the confluence of hepatic veins (COHV) and the portal vein bifurcation (PVB), were measured using CT scans after two and four chemotherapy cycles. Statistical analyses assessed changes in these parameters. RESULTS: The maximum tumor diameter decreased significantly after two cycles of chemotherapy (11.9±2.5 cm to 8.3±2.0 cm, p<0.0001) and further to 7.1±1.9 cm after four cycles. The distance to COHV (DSTCOHV) increased from 0.5±0.9 cm to 1.4±1.2 cm after two cycles (p<0.001) and to 1.6±1.4 cm after four cycles (p<0.0001). However, for distance to PVB (DSTPVB), the increase was more modest, from 0.1±0.3 cm to 0.6±0.5 cm after two cycles (p<0.001) and to 0.8±0.6 cm after four cycles (p<0.0001). Patients with limited response after two cycles gained minimal benefit from additional chemotherapy. CONCLUSIONS: Preoperative chemotherapy significantly reduces tumor size and improves surgical margins, particularly during the first two cycles. For tumors near PVB, prolonged chemotherapy may offer limited benefit, emphasizing the need for individualized treatment planning.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。